云(yun)頂(ding)(ding)新耀宣布，戰(zhan)(zhan)略增持I-Mab公(gong)(gong)司股(gu)(gu)權。云(yun)頂(ding)(ding)新耀將向(xiang)I-Mab公(gong)(gong)司投(tou)資3,090萬美(mei)元（折合約(yue)2.426億港(gang)元）。交易完成后，加上此前云(yun)頂(ding)(ding)新耀已(yi)持有的(de)I-Mab股(gu)(gu)份在內，公(gong)(gong)司將合計持有I-Mab約(yue)16.1%的(de)股(gu)(gu)份，成為I-Mab的(de)第一(yi)(yi)大股(gu)(gu)東(dong)。I-Mab是一(yi)(yi)家專注于(yu)腫瘤精準免(mian)疫(yi)治(zhi)療的(de)全(quan)(quan)球性生物技術公(gong)(gong)司，于(yu)美(mei)國納斯達克全(quan)(quan)球市場掛牌上市。此次增加對I-Mab的(de)戰(zhan)(zhan)略性股(gu)(gu)權投(tou)資，進一(yi)(yi)步推動了云(yun)頂(ding)(ding)新耀在全(quan)(quan)球范圍布局新一(yi)(yi)代腫瘤免(mian)疫(yi)治(zhi)療管線。（美(mei)通(tong)社）